Hepatocellular Carcinoma: Diagnosis and Treatment (Current Clinical Oncology)
Author: Brian I. Carr
Publication Year: 2018
Page Count: 617
Hepatocellular Carcinoma (HCC): Diagnosis and Treatment is a comprehensive, authoritative text that provides an in-depth exploration of the epidemiology, molecular biology, diagnosis, and therapeutic strategies for hepatocellular carcinoma. This third edition reflects significant advances in the field since 2009, integrating cutting-edge research on viral hepatitis, molecular profiling, immune therapies, and evolving clinical management paradigms. The book is structured into three main parts—Causes, Biological and Molecular Bases; Diagnosis; and Therapies—culminating in an integrative overview chapter. It is designed for clinicians, researchers, and specialists seeking a detailed, multidisciplinary understanding of HCC.
Scope and Purpose
This volume aims to synthesize the complex, multifactorial nature of HCC, emphasizing its diverse etiologies, molecular heterogeneity, and the interplay between tumor biology and the liver microenvironment. It addresses the global burden of HCC, highlighting geographic and demographic variations, and incorporates recent advances in antiviral therapies, molecular diagnostics, and novel treatment modalities including targeted agents, immunotherapy, and radiation techniques. The book also discusses psychosocial aspects and systemic evolutionary theories of cancer, providing a holistic perspective on HCC pathogenesis and management.
Intended Audience
The book targets hepatologists, oncologists, surgeons, radiologists, pathologists, and clinical researchers involved in liver cancer care and research. It is also valuable for trainees and specialists in molecular oncology and translational medicine who require a detailed understanding of HCC biology and evolving therapeutic approaches.
Part I: Causes, Biological and Molecular Bases of HCC
Preface and Overview
The third edition underscores major advances since 2009, including FDA approval of effective direct-acting antivirals (DAAs) for hepatitis C virus (HCV), recognition of cirrhosis and systemic inflammation as key prognostic factors, and the emergence of immune checkpoint inhibitors. Expanded liver transplantation criteria and safer regional therapies such as yttrium-90 (90Y) microspheres have improved treatment options. The rising incidence of obesity and nonalcoholic steatohepatitis (NASH)-associated HCC is noted as a growing concern. Despite several kinase inhibitors failing phase III trials, ongoing research targets tumor stem cells, dendritic cells, microRNAs, vaccines, radionuclides, and radiation therapies. The proliferation of staging systems reflects regional differences and evolving clinical needs. The SHARP trial highlighted discrepancies between tumor size response and survival benefit, prompting reconsideration of clinical trial endpoints. Advances in hepatitis prevention and treatment enable a continuum of HCC prevention from primary to tertiary levels.
Chapter 1: Epidemiology of Hepatocellular Carcinoma
HCC ranks as the fifth most common cancer worldwide and accounts for approximately 9.1% of cancer deaths. In 2012, there were an estimated 782,000 new cases and 746,000 deaths, predominantly in less developed regions such as Eastern and Southeastern Asia and sub-Saharan Africa, with China alone accounting for half of all cases. Incidence is rising in traditionally low-rate countries including the United States, United Kingdom, and Australia, driven by aging cohorts with chronic HCV infection, obesity, and diabetes. Males have a 2–4 fold higher incidence than females. Risk factors vary by geography and ethnicity.
Major Risk Factors:
- Hepatitis B Virus (HBV): The leading global cause, with 240 million chronic carriers. HBV infection increases HCC risk 5–15 fold. Antiviral therapy reduces but does not eliminate risk. Neonatal vaccination programs have reduced future disease burden.
- Hepatitis C Virus (HCV): The second leading cause, with 185 million infected worldwide. Cirrhosis develops in approximately 80% of chronic cases, with an annual HCC incidence of 2–5% among cirrhotics. DAAs introduced since 2014 have revolutionized treatment, though their impact on HCC incidence remains under study.
- Alcohol: Heavy consumption (>50–70 g/day) promotes cirrhosis and HCC, often synergizing with viral hepatitis and obesity.
- Aflatoxin B1: A mycotoxin causing characteristic p53 mutations, synergistic with HBV infection, prevalent in Africa and Asia.
- Diabetes and Obesity: Both independently increase HCC risk. Obesity promotes fibrosis and epigenetic changes, with NAFLD/NASH emerging as significant etiologies.
- Tobacco: Smoking increases risk by approximately 1.45-fold, with dose-dependent effects and synergy with other factors.
- Oral Contraceptives: Early high-dose formulations linked to benign liver tumors; no clear association with HCC.
- Dietary Factors: Coffee consumption reduces risk; tea effects are inconsistent; vegetable intake is protective; saturated fats may increase risk.
Chapter 2: Environmental Carcinogens and Risk for Human Liver Cancer
Aflatoxin contamination of staple foods remains a major risk factor, especially in conjunction with HBV infection. Biomarkers such as DNA and protein adducts enable exposure assessment and risk stratification. Chemopreventive agents like oltipraz and sulforaphane activate detoxifying enzymes via the Nrf2-Keap1 pathway, reducing aflatoxin-DNA adduct formation. The p53 codon 249 mutation serves as a molecular fingerprint of aflatoxin exposure and can be detected in plasma years before HCC diagnosis. While biomarkers are valuable for population-level interventions, their predictive power for individual risk remains limited.
Chapter 3: Molecular Mechanisms of Hepatocellular Carcinoma
HCC heterogeneity stems from diverse etiologies and cellular origins. Key molecular mechanisms include:
- Loss of Cell Cycle Control: Overexpression of cyclins D1 and E1; downregulation of inhibitors p16, p21, and p27 via promoter methylation and microRNAs.
- Escape from Senescence: Reactivation of telomerase through TERT promoter mutations; p53 mutations (notably codon 249); alterations in the RB pathway.
- Resistance to Cell Death: Evasion of apoptosis via downregulation of death receptors, overexpression of anti-apoptotic proteins, and NF-κB activation.
- Phenotypic Plasticity: Epithelial-mesenchymal transition (EMT) induced by TGF-β, Wnt/β-catenin, and Notch pathways promotes invasion and metastasis; mesenchymal-epithelial transition (MET) facilitates colonization.
- Tumor Microenvironment Remodeling: Diverse modes of cell migration (mesenchymal, amoeboid, collective) facilitate metastasis; circulating tumor cell clusters contribute to recurrence.
- Molecular Targets: c-Met, HIF-1α, and chemokine axes such as CXCL12/CXCR4 are implicated in tumor progression.
Chapter 4: Chemically-Induced Hepatocarcinogenesis
Chemical carcinogens induce liver tumors through genotoxic mechanisms (DNA adduct formation and mutations) and non-genotoxic pathways (altered proliferation and apoptosis). Key agents include aflatoxin, phenobarbital (tumor promoter via CAR activation), estrogens, dioxins (via AhR activation), ethionine, and peroxisome proliferators. Rodent models demonstrate initiation-promotion-progression stages, with preneoplastic lesions expressing GST-P. Genetic susceptibility varies by strain. Human HCC risk factors encompass viral hepatitis, alcohol, aflatoxin exposure, metabolic diseases, and genetic disorders such as hemochromatosis, Wilson’s disease, alpha-1 antitrypsin deficiency, and tyrosinemia. Molecular alterations involve p53, β-catenin, chromatin remodeling genes, and telomerase activation.
Chapter 5: Molecular Profiling of Human Hepatocellular Carcinoma
Molecular signatures derived from tumor and adjacent non-tumor liver tissue predict prognosis and recurrence risk. The liver microenvironment, particularly hepatic stellate cells interacting with monocytes, promotes tumor progression. MicroRNAs (miRNAs) regulate metastasis; for example, let-7g suppresses metastasis, while miR-517a promotes proliferation. AFP-positive and AFP-negative tumors differ in miRNA and methylation profiles. HCC exhibits significant inter- and intratumor heterogeneity, with subtypes defined by gene expression and signaling pathways including EGFR, Wnt, and mTOR. Stem cell-like subtypes express EpCAM and miR-181 family members. Advances in sequencing have identified driver mutations and viral integration sites. Circulating tumor cells correlate with recurrence risk. Integrative omics approaches facilitate patient stratification and precision medicine.
Chapter 6: Genomic Signatures of Risk Factors and Molecular Identification of HCC Subtypes
Most HCC arises in cirrhotic livers, though approximately 10% occur without cirrhosis. Genotoxic exposures such as aflatoxin induce characteristic TP53 mutations; HBV promotes insertional mutagenesis activating oncogenes like TERT and MLL4. TERT promoter mutations are early events in carcinogenesis. CTNNB1 and TP53 mutations define distinct molecular subgroups. Copy number alterations affect key pathways including telomere maintenance, Wnt, PI3K/mTOR, and p53. Mutation patterns vary by etiology: HBV-related HCC is enriched in TP53 mutations, whereas alcohol-related HCC shows more CTNNB1 and ARID1A mutations.
Chapter 7: MicroRNAs and Hepatocellular Carcinoma
MicroRNAs regulate gene expression post-transcriptionally and act as tumor suppressors or oncogenes. Aberrant miRNA expression in HCC influences proliferation, apoptosis, invasion, and metastasis. Circulating miRNAs such as miR-21 and miR-122 are promising noninvasive biomarkers for diagnosis and prognosis. miRNA profiles also modulate therapy response. Therapeutic strategies include miRNA mimics and inhibitors, though delivery challenges remain. Novel delivery methods involve nanoparticles and exosomes. miRNAs influence outcomes across surgery, radiotherapy, transarterial chemoembolization (TACE), chemotherapy, and targeted therapy.
Chapter 8: Nontumor Prognostic Factors in Hepatocellular Carcinoma
HCC risk and prognosis vary according to liver disease etiology, fibrosis stage, and metabolic factors such as obesity and diabetes. Surveillance with ultrasound is underutilized. Molecular prognostic markers include gene-expression signatures from non-tumoral liver tissue that predict recurrence and survival. Germline single nucleotide polymorphisms (SNPs) in genes such as PNPLA3, EGF, DEPDC5, and MHC loci associate with HCC risk. Activated hepatic stellate cell signatures correlate with disease progression. Emerging tools include liquid biopsy and imaging biomarkers. Integration of clinical and molecular data is essential for personalized risk stratification.
Chapter 9: Gut Microbiota and HCC
The gut microbiota influences liver disease progression and HCC development via bacterial translocation and pathogen-associated molecular patterns (PAMPs), notably lipopolysaccharide (LPS), which activate hepatic inflammation through Toll-like receptor 4 (TLR4) signaling. Altered microbiota composition, increased intestinal permeability, and small intestinal bacterial overgrowth contribute to chronic liver inflammation and fibrosis. Experimental models demonstrate that gut sterilization or TLR4 inhibition reduces HCC development. Obesity-associated microbiota changes increase deoxycholic acid production, inducing a senescence-associated secretory phenotype in hepatic stellate cells that promotes tumorigenesis. Therapeutic approaches include probiotics, fecal microbiota transplantation, antibiotics such as rifaximin, and TLR4 antagonists. However, caution is warranted due to potential dysbiosis and immune effects.
Chapter 10: Hepatocellular Carcinoma as a Paradigm for a Systemic Evolutionary Approach to Cancer
Traditional cancer theories focusing solely on somatic mutations or tissue organization have limitations. This chapter presents a systemic evolutionary theory viewing the eukaryotic cell as a symbiotic system composed of an informational subsystem (archaea) and an energetic subsystem (prokaryote-derived mitochondria). Cancer arises from "de-emergence," a disruption of this symbiosis via inflammation, mitochondrial damage, and nuclear DNA alterations, leading to uncoordinated cellular subsystems. This holistic framework integrates cellular and tissue-level processes, offering novel insights into cancer pathogenesis and potential therapeutic strategies.
Chapter 11: HCC and Its Microenvironment
HCC typically develops in chronically inflamed livers due to HBV, HCV, alcoholism, aflatoxin exposure, or obesity, often on a cirrhotic background. The tumor microenvironment, including stromal cells, endothelial cells, immune cells, and platelets, critically influences tumor progression. Stromal cells produce collagen that promotes tumor growth and angiogenesis. Chronic inflammation correlates with prognosis, and systemic inflammation is linked to outcomes; anti-inflammatory treatments may reduce HCC risk. Platelets contain growth factors such as EGF, PDGF, IGF-1, serotonin, and FGF that stimulate HCC proliferation. Thrombocytosis associates with aggressive tumors, while thrombocytopenia correlates with smaller tumors. Platelets can antagonize anti-tumor drugs like sorafenib and regorafenib by activating survival pathways, contributing to drug resistance. Targeting platelet-mediated pathways may enhance therapeutic efficacy.
Chapter 12: Circulating Tumor Cells (Liquid Tumor Biopsy) in HCC
Circulating tumor cells (CTCs) and circulating cancer stem cells (CCSCs) are emerging prognostic markers associated with metastasis and postoperative recurrence in HCC. CTCs exhibit genetic and phenotypic heterogeneity, complicating detection and therapeutic targeting. Liquid biopsy via CTCs offers a minimally invasive method for tumor genetic profiling, aiding early diagnosis, prognosis, treatment guidance, and monitoring. Detection methods include density centrifugation, microfiltration, immunological enrichment (positive and negative selection), and combined platforms such as CellSearch. Challenges include the rarity of CTCs, heterogeneity, and lack of universal markers; EpCAM-based methods may miss mesenchymal or stem-like CTCs. In HCC, markers such as ASGPR and CPS1 improve detection. Molecular profiling reveals mutations in β-catenin, TP53, and HER2, as well as epithelial-mesenchymal transition (EMT) markers correlating with invasiveness and therapy response. High preoperative CTC levels predict recurrence risk. Neoadjuvant therapies and surgical techniques minimizing CTC release may reduce metastasis. Postoperative CTC monitoring can guide personalized therapy. Further research is needed to standardize detection methods and validate clinical utility.
Chapter 13: Role of the Immune System in HCC
Chronic inflammation drives HCC development through immune cells including macrophages, Kupffer cells, T cells, and natural killer T (NKT) cells producing reactive oxygen and nitrogen species that cause DNA damage. Pattern-recognition receptors such as TLR4 activate proinflammatory pathways promoting tumor growth. Cytokines like interleukin-6 (IL-6) activate STAT3 signaling, correlating with HCC risk and sex differences. Tumor-associated macrophages (TAMs) promote epithelial-mesenchymal transition (EMT), invasiveness, and cancer stem cell proliferation. Conversely, tumor-infiltrating lymphocytes, especially CD8+ T cells, mediate antitumor immunity but often become dysfunctional due to inhibitory receptors (PD-1, Tim-3) and immunosuppressive cells such as regulatory T cells (Tregs) and myeloid-derived suppressor cells. Dendritic cells show impaired function, and natural killer (NK) cells are suppressed. Immunotherapy approaches include vaccines targeting tumor-associated antigens (AFP, glypican-3), adoptive T-cell transfer, dendritic cell vaccines, and immune checkpoint inhibitors (anti-PD-1, CTLA-4). Early clinical trials demonstrate immune activation and disease stabilization. Combination therapies and adjuvant immunotherapy are under investigation. Standard treatments like radiofrequency ablation (RFA) and transarterial chemoembolization (TACE) may enhance antitumor immunity.
Chapter 14: Inter- and Intratumor Heterogeneity in HCC
HCC exhibits extensive heterogeneity both between tumors (intertumor) and within individual tumors (intratumor), influencing progression, metastasis, recurrence, and treatment response. Intertumor heterogeneity arises from genetic and epigenetic differences and distinct cells of origin, leading to molecular subtypes with specific clinical behaviors. Intratumor heterogeneity encompasses genetic, epigenetic, and phenotypic diversity across spatial and temporal dimensions. Two models explain heterogeneity: the cancer stem cell hypothesis and clonal evolution. Molecular classifications identify subtypes such as progenitor-like (aggressive), bile duct epithelium-like (better prognosis), and hepatocyte-like. Genetic heterogeneity involves mutations in TP53, CTNNB1, and HBV integration patterns. Morphological and immunohistochemical heterogeneity complicate diagnosis and therapy. Tumor microenvironment heterogeneity includes variable immune cell infiltration and stromal activation influencing prognosis. Understanding heterogeneity is critical for personalized therapy development.
Chapter 15: Systemic Inflammation: Prognostic Domain and Therapeutic Target in HCC
Systemic inflammation is a key driver of HCC pathogenesis and progression. Peripheral blood markers such as neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), C-reactive protein (CRP), and albumin levels correlate with prognosis and have been combined into prognostic indices including the modified Glasgow Prognostic Score and Prognostic Nutritional Index. Elevated NLR and PLR reflect pro-tumor immune polarization and thrombocytosis, which promote tumor growth and therapy resistance. Anti-inflammatory agents such as aspirin and nonsteroidal anti-inflammatory drugs (NSAIDs), as well as molecular targeted therapies including JAK/STAT and TGF-β inhibitors, show potential therapeutic benefit. Immune checkpoint inhibitors are promising but face challenges related to viral hepatitis and immune-related toxicity. Inflammation-based scores may guide treatment stratification but require prospective validation and integration with clinical staging systems.
Chapter 16: Hepatocellular Carcinoma Associated with Hepatitis B Virus
HBV infection is a major global cause of HCC, particularly in Asia and Africa. The HBV genome encodes the HBx protein, which promotes carcinogenesis by enhancing viral replication, inducing fibrosis, modulating immune responses, generating oxidative stress, and integrating into the host genome to disrupt tumor suppressor genes and activate oncogenes. Risk factors include male sex, age over 40, high viral load, HBV genotype, alcohol consumption, and smoking. Universal HBV vaccination programs have reduced HBV prevalence and childhood HCC incidence. Antiviral therapies such as pegylated interferon and nucleos(t)ide analogues (lamivudine, entecavir, tenofovir) suppress viral replication, reduce fibrosis progression, and lower HCC risk but do not eliminate it. Surveillance with biannual ultrasonography is recommended for cirrhotic and high-risk non-cirrhotic HBV carriers; alpha-fetoprotein (AFP) testing has limited sensitivity. Post-HCC antiviral therapy reduces recurrence and improves survival. Challenges include antiviral resistance and poor surveillance adherence.
Chapter 17: Hepatitis C and Hepatocellular Carcinoma
HCV infection is a major cause of HCC, especially in Japan and Western countries. HCV is an RNA virus that does not integrate into the genome but promotes carcinogenesis through chronic inflammation, apoptosis, hepatocyte regeneration, and direct oncogenic effects of viral proteins. Antiviral therapy with interferon-based regimens and direct-acting antivirals (DAAs) achieving sustained virologic response reduces HCC risk. Surveillance is recommended for patients with advanced fibrosis or cirrhosis using ultrasound and AFP, though AFP sensitivity is limited. New serum markers and imaging modalities are under evaluation. Post-resection antiviral therapy improves survival and reduces recurrence. Prevention of recurrence remains challenging.
Chapter 18: Obesity, NASH, and HCC
Nonalcoholic fatty liver disease (NAFLD) and its progressive form nonalcoholic steatohepatitis (NASH) are increasingly important causes of HCC, linked to obesity, insulin resistance, and metabolic syndrome. Genetic variants such as PNPLA3 and TM6SF2 and gut microbiota dysbiosis contribute to disease progression. Diagnosis relies on imaging, liver biopsy, and noninvasive fibrosis scores. Lifestyle interventions including weight loss, Mediterranean diet, and exercise improve outcomes. Pharmacologic treatments like pioglitazone and vitamin E show moderate benefits but require further validation. NAFLD-related cirrhosis is a growing indication for liver transplantation.
Chapter 19: Metabolic Disease and Hepatocellular Carcinoma
Metabolic disorders including NAFLD/NASH, alcoholic liver disease, hemochromatosis, Wilson’s disease, and diabetes mellitus contribute to HCC risk through mechanisms involving oxidative stress, mitochondrial dysfunction, and altered cell proliferation and apoptosis. Alcohol promotes carcinogenesis indirectly via oxidative stress and methylation defects. Iron and copper overload generate reactive species causing DNA damage. Genetic and metabolic factors interact to increase HCC risk, often in cirrhotic livers. Surveillance is recommended in cirrhosis regardless of etiology.
Chapter 20: Aspects of Hepatocellular Tumor Pathology
Accurate diagnosis of HCC and its variants is essential for prognosis and therapy. Benign lesions include focal nodular hyperplasia (FNH) and hepatocellular adenoma (HCA), with subtypes defined by molecular features and risk of malignant transformation. Dysplastic nodules in cirrhosis represent preneoplastic stages. HCC shows variable morphology, growth patterns, and differentiation grades. Immunohistochemical markers such as HepPar-1, arginase-1, glypican-3, and AFP aid diagnosis. Variants include fibrolamellar HCC (characterized by DNAJB1-PRKACA fusion), clear cell HCC, scirrhous HCC, combined hepatocellular-cholangiocarcinoma, sarcomatoid HCC, and lymphoepithelial HCC. Hepatoblastoma is the common pediatric liver cancer with diverse histology and molecular features.
Chapter 21: Protein Biomarkers in HCC Management
Serum protein biomarkers complement imaging in HCC diagnosis and prognosis. AFP is widely used but has limited sensitivity. Des-gamma-carboxy prothrombin (DCP/PIVKA-II), AFP-L3, osteopontin, Golgi protein 73, and glypican-3 provide additional diagnostic and prognostic information. Combining biomarkers in statistical models improves accuracy. The GALAD score (Gender, Age, AFP, AFP-L3, DCP) predicts HCC probability and is validated across populations. The BALAD score incorporates bilirubin and albumin with biomarkers for prognosis. The ALBI score assesses liver function objectively. These models support personalized HCC management.
Chapter 22: Surveillance for Hepatocellular Carcinoma
Surveillance aims for early HCC detection to improve survival. Target populations include patients with cirrhosis of any etiology, chronic HBV carriers with active disease, and selected high-risk groups.
HBV Carriers: Viral load predicts HCC risk; screening recommended for Asian men ≥40 years, women ≥50 years; African carriers require earlier surveillance. HBV genotype affects risk. Nucleos(t)ide analog therapy reduces but does not eliminate HCC risk; surveillance continues after HBsAg clearance.
HCV Carriers: Screening endorsed for cirrhosis; HCC risk persists post-sustained virologic response (SVR); surveillance recommended even after viral clearance. Interferon therapy reduces but does not eliminate risk.
HIV Co-infection: Increases liver morbidity; HCC is more aggressive and occurs earlier; surveillance criteria are similar to mono-infection but may require adjustment.
Non-viral Cirrhosis: Alcohol increases HCC risk approximately fivefold, synergistic with HCV. NASH is recognized as a cause, sometimes without cirrhosis. Diabetes and obesity independently increase risk. Surveillance is recommended for alcoholic cirrhosis and metabolic diseases; not routinely for autoimmune hepatitis or alpha-1 antitrypsin deficiency.
Liver Transplant Candidates: Surveillance recommended for Child-Pugh C patients on waiting lists.
Screening Strategy: Semiannual ultrasound (US) is recommended; AFP use varies due to low sensitivity and specificity. US sensitivity ranges from 65–80%, specificity >90%, but is limited in obese or fatty liver patients. Combining AFP and US slightly increases detection but raises costs and false positives. Japanese guidelines recommend intensified screening every 3–4 months in high-risk patients, though evidence is lacking.
Recall Policy: Nodules smaller than 1 cm warrant follow-up US every 4 months in the first year, then every 6 months. Diagnosis relies on imaging hallmarks of arterial enhancement and portal/delayed washout on CT or MRI. Contrast-enhanced ultrasound (CEUS) has been dropped from AASLD/EASL guidelines due to false positives with cholangiocarcinoma. Nodules 1–2 cm require sequential CT or MRI; biopsy is indicated if imaging is inconclusive. Biopsy carries a tumor seeding risk of approximately 2.9%; immunostaining with glypican-3, HSP70, and glutamine synthetase aids differentiation.
Efficacy of Surveillance: Surveillance detects small, treatable HCCs and reduces liver-specific mortality by 19–63%. A randomized controlled trial in Shanghai demonstrated mortality reduction with US and AFP screening. Observational studies confirm improved survival despite potential biases. Patient acceptance is high, but physician adherence varies due to knowledge gaps and access barriers.
Economic Consequences: Combined AFP and US every 6 months is cost-effective, with cost-utility estimated at approximately US$60,000 per quality-adjusted life year (QALY).
Optimizing Surveillance: Risk scores such as REACH-B, GAG, CU-HCC, and PAGE-B identify low- and high-risk patients but show variable performance. Ethical concerns exist regarding withholding surveillance from low-risk individuals.
Conclusions: Surveillance increases early detection and survival and remains practical despite the lack of randomized trials. Education and community-based screening programs may improve outcomes.
Chapter 23: Use of Imaging Techniques to Screen Hepatocellular Carcinoma
Imaging assesses liver morphology, vasculature, portal hypertension, and detects focal masses. Serum markers such as AFP and PIVKA-II complement imaging. Fibrosis and regenerative nodules have characteristic imaging features; dysplastic nodules are premalignant and challenging to differentiate. Small HCC detection requires contrast-enhanced multiphasic CT and MRI, with arterial hyperenhancement and portal/delayed washout as diagnostic hallmarks. Liver-specific MR contrast agents improve early HCC detection. Ultrasound sensitivity is limited (~21–30% for small HCC); CT and MRI are more sensitive but still imperfect. Guidelines recommend ultrasound every 6 months with AFP; abnormal findings prompt CT or MRI. Surveillance intervals are based on tumor doubling time (~6 months). Imaging protocols should adapt to local resources and patient factors.
Chapter 24: Ultrasound of Hepatocellular Carcinoma: The Important Contribution of Contrast Enhancement
Contrast-enhanced ultrasound (CEUS) provides real-time hemodynamic assessment using intravascular microbubble contrast agents. The CEUS protocol includes arterial, portal, and late phases; typical HCC shows arterial hyperenhancement and late washout (>90 seconds). CEUS is superior to CT and MRI in detecting arterial phase hypervascularity due to real-time imaging. It differentiates HCC from cholangiocarcinoma and benign lesions and is useful in patients with renal failure and for guiding or monitoring local ablation therapies. Limitations include operator dependency and limited whole-liver coverage; CT and MRI remain standard for staging. CEUS is safe, with low adverse event rates, no nephrotoxicity, and no radiation exposure. It is included in diagnostic algorithms in many countries, and the Liver Imaging Reporting and Data System (LI-RADS) incorporates CEUS.
Chapter 25: MRI for Detection and Evaluation of Hepatocellular Carcinoma
MRI differentiates fibrosis, regenerative nodules, dysplastic nodules, and HCC based on signal characteristics and enhancement patterns. LI-RADS standardizes imaging diagnosis with categories ranging from definitely benign to definite HCC. MRI protocols include in-phase/opposed-phase imaging, T2-weighted, and T1-weighted dynamic contrast sequences. Major diagnostic features include arterial hyperenhancement, washout, capsule appearance, and lesion growth. Ancillary features help refine diagnosis. Limitations include some HCCs showing hepatobiliary phase uptake and heterogeneous cirrhotic liver background.
Chapter 26: Computed Tomography of HCC
Contrast-enhanced multiphasic CT is the primary imaging modality for diagnosis, staging, and treatment planning. Protocols include unenhanced, arterial, portal venous, and delayed phases. Regenerative nodules are usually isoattenuating; dysplastic nodules may show arterial enhancement. HCC typically demonstrates arterial hyperenhancement and portal/delayed washout; the capsule may enhance progressively. Multiplanar and three-dimensional reconstructions aid evaluation.
Chapter 27: Clinical Features and Clinician’s Diagnostic Approach to Hepatocellular Carcinoma
HCC is common worldwide, mostly linked to HBV and HCV infections, with rising incidence due to HCV, obesity, and NASH. Clinical presentation ranges from asymptomatic to symptomatic with pain, weight loss, portal vein thrombosis (PVT), tumor rupture, and paraneoplastic syndromes. PVT occurs in 34–50% of cases; malignant PVT worsens prognosis and contraindicates transplantation. Screening is recommended in cirrhotics and high-risk HBV carriers, with ultrasound every 6 months as standard; AFP use remains controversial. Diagnosis relies on imaging showing arterial hyperenhancement and washout; CEUS use is debated. Lesions smaller than 1 cm are monitored; lesions larger than 1 cm with typical imaging are diagnosed; atypical lesions require biopsy. The Barcelona Clinic Liver Cancer (BCLC) staging system is widely used; Milan criteria define transplant eligibility. Liver biopsy is recommended for atypical lesions but carries risks including tumor seeding. Primary prevention includes HBV vaccination; antiviral therapy reduces recurrence after curative treatment.
Chapter 28: Current HCC Staging Systems: Their Uses and Limitations
Multiple staging systems integrate tumor burden and liver function, with geographic variations affecting applicability. The TNM system focuses on tumor extent but lacks liver function assessment. Conventional systems such as Okuda and GRETCH are less precise currently. Systems designed for treatable conditions (CLIP, JIS, Tokyo, TIS, BALAD, MITS) have been validated mainly in Asia. Advanced condition systems (CUPI, ALCSG) predict prognosis in advanced disease. Treatment recommendation systems such as BCLC and HKLC guide therapy; BCLC is widely endorsed. No universal system fits all patients; regional differences and patient characteristics influence choice.
Chapter 29: Percutaneous Ethanol Injection (PEI)
PEI involves image-guided ethanol injection causing tumor necrosis and is effective for small tumors ≤3 cm. Multiple sessions are usually required; single-session PEI for larger tumors carries higher complication rates. Mortality is low (~0.09%), with major complications occurring in 1.3–2.4% of cases. Five-year survival ranges from 43–63% in selected patients. PEI is less effective than radiofrequency ablation (RFA) but remains valuable where RFA is unavailable or contraindicated. Combined therapies such as PEI plus RFA or TACE improve outcomes. PEI is cost-effective and useful for downstaging before transplantation.
Chapter 30: Thermal Ablative Treatments for Hepatocellular Carcinoma
RFA is the first-line treatment for early unresectable HCC, achieving 5-year survival rates of 40–70%. Microwave ablation (MWA) offers larger ablation zones and shorter procedure times; safety is established but survival benefit over RFA remains unproven. High-intensity focused ultrasound (HIFU) and laser ablation are emerging options with promising results in specialized centers. Cryoablation induces necrosis via freezing, with local control comparable to RFA; complications include hemorrhage and cryoshock. Combination therapies such as TACE plus RFA improve outcomes compared to RFA alone. RFA is superior to PEI in local control and survival, especially for tumors larger than 2 cm.
Chapter 31: Resection of Hepatocellular Carcinoma
Resection is a curative option for non-cirrhotic or well-compensated cirrhotic patients without portal hypertension. Portal hypertension is assessed clinically and via hepatic venous pressure gradient (HVPG); its presence reduces resectability and worsens outcomes. Preoperative evaluation includes imaging, liver function assessment, and future liver remnant volume calculation. Anatomical resection with wide margins is preferred. Minimally invasive techniques such as laparoscopic resection are safe and yield similar oncologic outcomes. Recurrence is common (~75% at 5 years); antiviral therapy reduces recurrence risk. Repeat resection and salvage transplantation are options for recurrence.
Chapter 32: Liver Transplantation for Hepatocellular Carcinoma
Liver transplantation (LT) cures both tumor and underlying liver disease. The Milan criteria remain the standard for listing, but expanded criteria such as UCSF and "up to 7" have shown comparable survival with careful selection. AFP levels and dynamics predict recurrence and survival. Downstaging therapies including RFA, TACE, and radioembolization reduce dropout rates and improve outcomes. Living donor LT shortens wait times but raises ethical concerns; survival is comparable within Milan criteria. Adjuvant therapies post-LT remain unproven; immunosuppression impacts recurrence risk. Mammalian target of rapamycin (mTOR) inhibitors may reduce recurrence; ongoing trials are evaluating this.
Chapter 33: Medical Therapy of HCC
Most patients present with advanced disease or impaired liver function, limiting curative options. Systemic therapies have evolved with the introduction of targeted agents and immunotherapies. Sorafenib remains the first-line standard for advanced HCC but has notable toxicities. Combination therapies with TACE or radiation are under study. New agents targeting molecular pathways and immune checkpoints are in clinical trials.
Chapter 34: Targeted Therapies for Hepatocellular Carcinoma
Personalized medicine is emerging, with MET-high tumors responding to tivantinib currently under phase III evaluation. Multiple targeted agents including regorafenib, cabozantinib, lenvatinib, brivanib, and ramucirumab, as well as combinations with sorafenib, are in clinical trials. Key molecular targets include Ras/Raf/MEK/ERK, VEGF/VEGFR, mTOR, Wnt, NF-κB, EGFR, and c-MET pathways. Resistance to antiangiogenic therapy remains a major challenge. Immune checkpoint inhibitors targeting PD-1/PD-L1 show promise. Sorafenib remains first-line but with limitations; combination therapies with TACE or radiation are being explored. Vaccination against HBV and antiviral therapy reduce HCC risk and recurrence.
Chapter 35: Radiation Therapy for Hepatocellular Carcinoma
35.1 Overview
Radiation therapy was historically limited by liver tolerance but advances now allow higher doses with sparing of normal tissue. Brachytherapy delivers high-dose localized radiation with minimal exposure to normal tissue.
35.2 Physics of Radiation Therapy
External beam radiation therapy (EBRT) uses photons or particles; linear accelerators produce high-energy photons for deep tumors. Techniques include 3D conformal radiation therapy (3D-CRT), 4D-CRT with respiratory gating, intensity-modulated radiation therapy (IMRT), stereotactic body radiation therapy (SBRT) with high-dose hypofractionation, and image-guided radiation therapy (IGRT). Brachytherapy uses radioactive sources placed near tumors; yttrium-90 (90Y) microspheres are common in liver-directed therapy.
35.3 Radiobiology
Radiation kills cells primarily via DNA damage mediated by free radicals; oxygen enhances this effect. Fractionation allows normal tissue repair; brachytherapy delivers continuous low-dose radiation.
35.4 Radiation Effects in the Liver
Acute effects include transient enzyme elevation and hematologic changes. Late effects include fibrosis, radiation-induced liver disease (RILD), and veno-occlusive disease. Whole liver tolerance is approximately 30–35 Gy; partial liver tolerates higher doses.
35.5 Clinical Studies
35.5.1 External Beam Radiation Therapy (EBRT)
Advances in 3D-CRT and combined therapies have improved tumor response and survival with acceptable toxicity. Dose escalation up to 90 Gy in partial liver irradiation shows tumor control. EBRT combined with TACE improves outcomes over TACE alone. Proton beam therapy offers precise dose delivery; Japanese data show high local control and response rates. SBRT achieves 1-year survival rates of 48–79%; combined with TACE shows high response and median survival around 25 months. EBRT is effective in treating portal vein thrombosis (PVT).
35.5.2 Brachytherapy
131I-lipiodol delivers beta radiation via the hepatic artery; response rates range from 25–70% in unresectable HCC and improve survival in PVT and post-resection settings. 90Y microspheres (radioembolization) deliver localized beta radiation; patient screening for lung shunting is essential. Radioembolization is safe and effective in PVT where TACE is contraindicated, with median survival of 10–17 months in Child-Pugh A patients. Transarterial radioembolization (TARE) facilitates downstaging and contralateral lobe hypertrophy aiding resection. Combination with sorafenib shows promising disease control. Guidelines vary; the Radioembolization Brachytherapy Oncology Consortium (REBOC) provides consensus recommendations emphasizing safety and multidisciplinary care. Two FDA-approved devices include TheraSphere® (glass microspheres) and SIR-Spheres® (resin microspheres). Tumor response is dose-dependent; toxicity is generally manageable.
Chapter 36: Psychosocial Issues in Hepatocellular Carcinoma
Psychosocial distress is common in HCC patients and impacts fatigue, treatment adherence, and survival. Liver cancer ranks high in distress prevalence. Risk factors include HBV/HCV infection, alcohol use, NASH, obesity, diabetes, and substance abuse; chronic inflammation promotes tumorigenesis. Depression and inflammation are bidirectionally linked; psychological interventions and pharmacotherapy can improve symptoms and possibly outcomes. Screening tools assess distress, depression, anxiety, fatigue, pain, sleep, cognition, and substance use. Adjustment disorder, major depressive disorder, anxiety disorders, post-traumatic stress disorder (PTSD), and substance abuse are prevalent psychiatric conditions. Substance abuse evaluation is critical due to its impact on liver disease and treatment complications; smoking cessation reduces surgical risks. Cancer-related symptoms include fatigue, pain, sleep disturbances, nausea, sexual dysfunction, and cognitive impairment; management involves pharmacologic and behavioral strategies tailored to cirrhosis and cancer context. Special issues include caregiver stress, cultural factors, end-of-life planning, and complementary medicine use (e.g., milk thistle). Psychosocial support and multidisciplinary care improve quality of life.
Chapter 37: Bringing It All Together
37.1 Prevention
Prevention focuses on HBV vaccination, antiviral therapy for HBV and HCV, lifestyle modifications, and reducing aflatoxin exposure. Understanding carcinogenesis mechanisms aids in developing prevention strategies.
37.2 Surveillance
Semiannual ultrasound and AFP screening in at-risk populations enable early detection and curative treatment. AFP sensitivity is limited; the cost-benefit of screening is debated, but early detection improves outcomes.
37.3 Current Therapy
Treatment depends on tumor size, number, vascular invasion, and liver function (Child-Pugh score). Liver resection is indicated for non-cirrhotic or Child-Pugh A patients without portal hypertension; laparoscopic and ablative therapies are increasingly used. High recurrence rates post-resection may be reduced by antiviral therapy. Liver transplantation is preferred within Milan criteria; extended criteria and downstaging protocols are under evaluation. TACE is standard for unresectable patients with preserved liver function; combination with ablation may improve outcomes. 90Y radioembolization is an alternative regional therapy; direct comparisons with TACE are lacking. Sorafenib is limited in the adjuvant setting but used in advanced disease. Portal vein thrombosis limits TACE use; 90Y and sorafenib are safer options. EBRT is emerging for unresectable patients with PVT. Clinical trials are recommended for patients failing standard therapies.
Multidisciplinary Team
Optimal management requires collaboration among hepatology, surgery, radiology, pathology, nuclear medicine, nursing, social work, and psychology. Coordinated care with patient navigation improves outcomes.
New Concepts and Controversies
Tumor biopsy is increasingly important for molecular profiling and personalized therapy; liquid biopsy is promising. Molecular classification predicts prognosis and therapy response; biobanking is essential. Response assessment includes vascular criteria (mRECIST) beyond size. New agents targeting growth pathways and immune checkpoints (e.g., PD-1 inhibitors) are in trials. The tumor microenvironment and inflammation influence biology and therapy. Prevention and early diagnosis remain critical to improve curative treatment rates.
Summary Table (2014 KLCSG-NCC Korea Guidelines)
- Prevention: HBV vaccination, antiviral therapy, lifestyle changes.
- Diagnosis: Imaging criteria; biopsy when needed.
- Treatment: Resection, ablation, transplantation, TACE, 90Y spheres, sorafenib per stage and liver function.
- Cautions: TACE contraindicated in main stem PVT; 90Y safer; EBRT emerging.
- Clinical Trials: Encouraged for advanced disease.
Index Highlights
Key terms include tumor-associated antigens and macrophages, VEGFR, XIAP, AFP, Wilson’s disease, tyrosinemia, viral hepatitis, vascular tumors, 90Y spheres, vitamins E and K, type 2 diabetes mellitus (T2DM), imaging modalities, and molecular regulators such as Zeb and ZHX2. The index reflects the multidisciplinary nature of HCC research spanning molecular biology, diagnostics, and therapeutics.
Notable Strengths
- Comprehensive integration of epidemiology, molecular biology, clinical diagnosis, and treatment.
- Detailed coverage of emerging molecular and immunologic insights.
- Inclusion of psychosocial and systemic evolutionary perspectives.
- Balanced discussion of diagnostic imaging modalities and surveillance strategies.
- Thorough review of current and emerging therapies, including targeted agents and radiation techniques.
- Emphasis on multidisciplinary care and personalized medicine.
Limitations and Cautions
- Rapidly evolving field means some therapeutic recommendations may require updating as new trial data emerge.
- Some surveillance and treatment strategies vary regionally; applicability may differ by healthcare setting.
- Biopsy and liquid biopsy techniques require further standardization before widespread clinical adoption.
- Psychosocial interventions, while emphasized, may be underrepresented in clinical practice due to resource constraints.
Utility in Cancer-Options Reference Database
This book serves as a foundational reference for understanding the complex biology and clinical management of hepatocellular carcinoma. Its detailed molecular insights support research into targeted therapies and biomarker development. The comprehensive review of diagnostic imaging and surveillance protocols aids clinicians in early detection strategies. The extensive discussion of therapeutic modalities, including ablative, surgical, transplant, systemic, and radiation therapies, provides evidence-based guidance for treatment planning. The inclusion of psychosocial and systemic perspectives enriches holistic patient care approaches. Overall, this text is a valuable resource for multidisciplinary teams managing HCC and for researchers developing novel interventions.
